- Home
- ZVIA vs ENGN Comparison
ZVIA vs ENGN Comparison
Compare ZVIA & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVIA
- ENGN
- Stock Information
- Founded
- ZVIA 2007
- ENGN 1999
- Country
- ZVIA United States
- ENGN Canada
- Employees
- ZVIA N/A
- ENGN N/A
- Industry
- ZVIA Beverages (Production/Distribution)
- ENGN
- Sector
- ZVIA Consumer Staples
- ENGN
- Exchange
- ZVIA Nasdaq
- ENGN Nasdaq
- Market Cap
- ZVIA 266.6M
- ENGN 317.6M
- IPO Year
- ZVIA 2021
- ENGN N/A
- Fundamental
- Price
- ZVIA $3.79
- ENGN $6.47
- Analyst Decision
- ZVIA Hold
- ENGN Strong Buy
- Analyst Count
- ZVIA 4
- ENGN 9
- Target Price
- ZVIA $2.69
- ENGN $29.78
- AVG Volume (30 Days)
- ZVIA 947.7K
- ENGN 176.0K
- Earning Date
- ZVIA 02-25-2025
- ENGN 03-10-2025
- Dividend Yield
- ZVIA N/A
- ENGN N/A
- EPS Growth
- ZVIA N/A
- ENGN N/A
- EPS
- ZVIA N/A
- ENGN N/A
- Revenue
- ZVIA $153,385,000.00
- ENGN N/A
- Revenue This Year
- ZVIA N/A
- ENGN N/A
- Revenue Next Year
- ZVIA $7.90
- ENGN N/A
- P/E Ratio
- ZVIA N/A
- ENGN N/A
- Revenue Growth
- ZVIA N/A
- ENGN N/A
- 52 Week Low
- ZVIA $0.62
- ENGN $4.42
- 52 Week High
- ZVIA $4.99
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- ZVIA 44.68
- ENGN 50.46
- Support Level
- ZVIA $3.60
- ENGN $6.20
- Resistance Level
- ZVIA $4.51
- ENGN $7.70
- Average True Range (ATR)
- ZVIA 0.34
- ENGN 0.84
- MACD
- ZVIA -0.14
- ENGN -0.02
- Stochastic Oscillator
- ZVIA 13.67
- ENGN 54.19
About ZVIA Zevia PBC
Zevia PBC is a beverage company disrupting the liquid refreshment beverage industry through refreshing, zero-calorie, zero-sugar, naturally sweetened beverages that are all Non-GMO Project Verified. It offers a platform of products that include a variety of flavors across Soda, Energy Drinks, Organic Tea, Mixers, Kidz drinks, and Sparkling Water. Its products are distributed across the U.S. and Canada through a network of retailers in the food, drug, mass, natural, and e-commerce channels. The company derives a majority of its revenue from the United States.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.